跳至主要内容
临床试验/NCT02961868
NCT02961868已完成不适用

PROgression of FIbromuscular LEsions

Assistance Publique - Hôpitaux de Paris34 个研究点 分布在 2 个国家目标入组 340 人开始时间: 2009年11月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
340
试验地点
34
主要终点
Progression of fibromuscular dysplasia lesions confirmed by imaging

研究概览

简要总结

PROFILE is a cohort study evaluating the progression of fibromuscular dysplasia lesions. This study is the prospective dimension of ARCADIA registry (ClinicalTrials.gov Identifier: NCT02884141), which aims to document phenotypic and genetic traits in patients with renal and/or cervical artery fibromuscular dysplasia.

详细描述

Background

Fibromuscular dysplasia (FMD) is a group of nonatherosclerotic, noninflammatory arterial diseases that usually involve renal and carotid arteries. Patients with FMD may present with renovascular hypertension and/or with cerebrovascular symptoms. The prevalence of FMD in hypertensive patients is estimated at 4/1000. Angiographic classification includes the multifocal type, with multiple stenoses and the 'string-of-beads' appearance that is related to medial FMD, and tubular and focal types which are not clearly related to specific histological lesions. FMD may affect one or more vascular beds and progress to more severe stenosis and to renal or cerebrovascular complications. FMD appears to be familial in 10% of cases (OMIM #135580).

Renal artery FMD may progress to more severe stenosis and to renal atrophy, and/or to stenoses affecting more arteries within or outside the renal vasculature. The risk of progression as assessed from available studies was probably overestimated because documentation of progression was obtained from angiography, a procedure which is not routinely undertaken in patients with favourable clinical and biological outcomes. The disease is progressive, however, and literature stated that patients with FMD should undergo yearly duplex ultrasonography to detect progression of disease, restenosis, or loss of kidney volume.

There are very few data on prognosis of patients with symptomatic carotid or vertebral artery FMD. The risk of arterial disease progression over time is unknown. The risk of ischemic stroke ranged from 0 to about 3% per year in the few studies which assessed that issue.

Objectives

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with renal or craniocervical fibromuscular dysplasia diagnosed during the 2 years before inclusion
  • The fibromuscular dysplasia is documented by imaging (angiography, CT-angiography, MR-angiography) of less than 2 years and validated by a radiologist investigator
  • Patient who understood and signed inform consent form
  • Affiliated to the French health insurance system
  • Available for a 3 years follow-up

排除标准

  • Patient with renal or craniocervical atherosclerosis, or inflammatory vascular disease as dominant pathological features
  • Patient with renal or craniocervical arteries dissection or aneurysm without any other evidence of fibromuscular dysplasia
  • Patient under 18 or under tutorship
  • Known pregnancy

研究组 & 干预措施

Prospective cohort

Experimental

3 years follow-up

干预措施: Abdominal and supra-aortic trunks vascular imaging (Other)

Prospective cohort

Experimental

3 years follow-up

干预措施: Blood sampling (genetic) (Genetic)

Prospective cohort

Experimental

3 years follow-up

干预措施: Blood sampling (biomarkers) (Other)

Prospective cohort

Experimental

3 years follow-up

干预措施: Urine sampling (Other)

结局指标

主要结局

Progression of fibromuscular dysplasia lesions confirmed by imaging

时间窗: 3 years

次要结局

  • Prevalence of multisite fibromuscular dysplasia confirmed by imaging(Inclusion, 3 years)
  • Clinical event: revascularization procedure in a lesion site(Through study completion)
  • Clinical event: renal infarction(Through study completion)
  • Clinical event: arterial dissection in a lesion site or downstream from a lesion site(Through study completion)
  • Glomerular filtration rate (GFR)(Inclusion, 3 years)
  • Clinical event: ischemic stroke(Through study completion)
  • Single nucleotide polymorphisms(Inclusion)
  • Plasminogen/plasmin level(Inclusion)
  • Clinical event: aneurysm rupture in a lesion site or downstream from a lesion site(Through study completion)
  • Kidney height(Inclusion, 3 years)
  • Matrix metalloproteinases level(Inclusion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (34)

Loading locations...

相似试验